1-diallylaminopropan-2-ol | 14377-30-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-diallylaminopropan-2-ol
• 英文别名: N,N-Diallyl-2-hydroxy-propylamin；1-Diallylamino-propanol-2；1-[Bis(prop-2-enyl)amino]propan-2-ol
• CAS: 14377-30-1
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: BLABOOCLGHYPFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-diallylaminopropan-2-ol 在 三溴化磷 作用下， 以 氯仿 为溶剂， 生成 N.N-Diallyl-2-brom-propylamin
  参考文献：
  名称：

  265.二-N-取代的2-卤代乙胺。第六部分 NN-二烷基-（或N-烷基）-2-烷基（或芳基或芳基烷基）衍生物：合成，反应性和药理学

  摘要：

  DOI：

  10.1039/jr9630001385
• 作为产物：
  描述：

  二烯丙基胺 、 methyloxirane 在 1,3-双[3,5-双(三氟甲基)苯基]硫脲 作用下， 以 水 为溶剂， 反应 36.0h， 以87%的产率得到1-diallylaminopropan-2-ol
  参考文献：
  名称：

  Hydrophobic amplification of noncovalent organocatalysis

  摘要：

  氢键有机催化剂和水对多种亲核试剂促进环氧化物开环反应的效果是相加的，并且在水中催化反应的产率极高。

  DOI：

  10.1039/b605850g

文献信息

• [EN] "A NOVEL PROCESS FOR CHIRAL RESOLUTION OF HIGHLY PURE (6R)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-3-HEPTANONE FROM RACEMIC METHADONE HYDROCHLORIDE"<br/>[FR] NOUVEAU PROCÉDÉ DE RÉSOLUTION CHIRALE DE (6R)-6-(DIMÉTHYLAMINO)-4,4-DIPHÉNYL-3-HEPTANONE DE HAUTE PURETÉ À PARTIR DE CHLORHYDRATE DE MÉTHADONE RACÉMIQUE
  申请人：HARMAN FINOCHEM LTD

  公开号：WO2016103274A1

  公开（公告）日：2016-06-30

  The present invention discloses an improved process for preparing pure (dimethylarnino)-4,4-diphenyl-3-heptanone and its hydrochloride salt.

  本发明公开了一种改进的制备纯（二甲基氨基）-4,4-二苯基-3-庚酮及其盐酸盐的方法。
• PROCESS FOR THE PREPARATION OF CROSS-LINKED POLYALLYLAMINES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
  申请人：GABOARDI Mauro

  公开号：US20120196988A1

  公开（公告）日：2012-08-02

  The present invention relates to a process for the preparation of cross-linked polyallylamines or pharmaceutically acceptable salts thereof. The invention further relates to a process for the preparation of Sevelamer or pharmaceutically acceptable salts thereof, preferably hydrochloride or carbonate salts, used in the treatment of hyperphosphatemia, and having good flowability, low porosity and/or a swelling index of between 7 and 9.

  本发明涉及一种制备交联聚丙烯胺或其药学上可接受的盐的过程。本发明还涉及一种制备Sevelamer或其药学上可接受的盐的过程，优选氯化物盐或碳酸盐，用于治疗高磷血症，具有良好的流动性，低孔隙度和/或7至9之间的膨胀指数。
• A method of forming an image, and an imaging element for inhibiting image formation with cobalt (III) complexes
  申请人：EASTMAN KODAK COMPANY (a New Jersey corporation)

  公开号：EP0003263A1

  公开（公告）日：1979-08-08

  An imaging element contains an energy-activatable image precursor composition comprising a cobalt III complex having releasable ligands which react with an image forming material to form a visible image. The element also contains a photoinhibitor which, on activating exposure, inhibits the release of ligands from the cobalt III complex or inhibits their image forming action. Images may be formed by imagewise activating the photoinhibitor, preferably with radiation longer than 300 nm, and thereafter activating the image precursor composition, for instance by heating. Images of a different sense may be formed by varying the exposure and activation treatments of the element.

  一种成像元件包含一种能量可激活的成像前体组合物，该组合物由钴 III 复合物组成，该钴 III 复合物具有可释放的配体，这些配体与成像材料反应形成可见图像。 该元件还包含一种光抑制剂，该光抑制剂在激活曝光时可抑制配体从钴 III 复合物中释放或抑制其成像作用。 可以通过成像激活光抑制剂（最好使用长于 300 纳米的辐射），然后激活成像前体组合物（例如通过加热）来形成图像。 可以通过改变元件的曝光和激活处理来形成不同意义的图像。
• Improved emulsion polymerization process utilizing a specifically defined ethylenically unsaturated polymerizable water-soluble nonionic surfactant formed by the reaction of a diallylamine, ethylene oxide, and propylene oxide and/or butylene oxide
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP0737693A1

  公开（公告）日：1996-10-16

  An improved emulsion polymerization process utilizing at least one substantially water-insoluble ethylenically unsaturated monomer is provided for forming discrete solid polymeric particles suitable for use in coating and/or adhesive applications. During at least the initial portion of the polymerization a dissolved water-soluble polymerizable surfactant (as defined) formed by the reaction of a diallylamine, ethylene oxide, and propylene oxide and/or butylene oxide additionally is provided in the reaction zone in the continuous aqueous phase. The water-soluble polymerizable surfactant undergoes copolymerization and is substantially completely consumed during the course of the emulsion polymerization. The emulsion polymerization is carried out on a stable basis, there is no need to attempt to remove a surfactant at the conclusion of the emulsion polymerization, and the resulting polymeric particles are particularly well suited for coating and/or adhesive end uses where they form stable films and exhibit improved adhesion characteristics.

  本发明提供了一种利用至少一种基本不溶于水的乙烯基不饱和单体的改进型乳液聚合工艺，用于形成适用于涂料和/或粘合剂应用的离散固体聚合物颗粒。至少在聚合的初始阶段，在连续水相的反应区中提供由二烯丙基胺、环氧乙烷、环氧丙烷和/或环氧丁 烷反应形成的溶解的水溶性可聚合表面活性剂（如定义）。水溶性可聚合表面活性剂发生共聚，并在乳液聚合过程中消耗殆尽。乳液聚合是在稳定的基础上进行的，在乳液聚合结束时无需试图去除表面活性剂，所得到的聚合物颗粒特别适用于涂料和/或粘合剂的最终用途，它们可以形成稳定的薄膜并表现出更好的粘合特性。
• COMPOSITIONS FOR TREATING ACID-BASE DISORDERS
  申请人：Tricida Inc.

  公开号：EP3831395A1

  公开（公告）日：2021-06-09

  Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

  用于治疗动物（包括人）的药物组合物和方法，以及制备这种组合物的方法。这些药物组合物含有不可吸收的成分，可用于治疗疾病或其他代谢状况，在这些疾病或代谢状况中，从胃肠道中清除质子、强酸的共轭碱和/或强酸将带来生理益处，例如使动物（包括人类）的血清碳酸氢盐浓度和血液 pH 值正常化。